Treatment of metastatic renal cell carcinoma with subcutaneous interleukin 2: evidence for non-renal clearance of cytokines
1997

Using Interleukin 2 to Treat Kidney Cancer

Sample size: 9 publication Evidence: moderate

Author Information

Author(s): RE Banks, MA Forbes, S Hallam, A Jenkins, M Wadhwa, P Dilger, A Meager, R Thorpe, CJ Bowmer, JK Joffe, P Patel, PWM Johnson, PJ Selby

Primary Institution: Imperial Cancer Research Fund Cancer Medicine Research Unit, St James's University Hospital

Hypothesis

The study investigates the pharmacokinetics of subcutaneous interleukin 2 (IL-2) in patients with metastatic renal cell carcinoma, particularly focusing on non-renal clearance mechanisms.

Conclusion

Subcutaneous administration of low-dose IL-2 shows that renal clearance is not significant, making it a preferred treatment option for patients with impaired renal function.

Supporting Evidence

  • The pharmacokinetics of IL-2 were similar in both anephric and normal patients.
  • Renal clearance of IL-2 is not significant for low-dose subcutaneous administration.
  • Patients with normal renal function and those on dialysis showed similar cytokine profiles.

Takeaway

This study shows that a treatment for kidney cancer using a substance called interleukin 2 can work well even for patients who don't have kidneys, and it doesn't cause more side effects than in patients with healthy kidneys.

Methodology

Patients received a combination of interferon a, IL-2, and 5-fluorouracil, with blood samples taken to measure cytokine levels.

Limitations

The study had a limited number of sampling points, making detailed pharmacokinetic analysis difficult.

Participant Demographics

Eight patients (three female, five male, age range 34-67 years) with advanced renal cell carcinoma were studied.

Statistical Information

P-Value

p<0.001

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication